Abstract
The purpose of this note is to posit and discuss the concept of "competitive inhibition potential" (CIP), which is an in vivo index of the ability of a competitive inhibitor to elevate plasma concentrations of drug substrates, when the competitive inhibitor is administered at its usual and customary dose.
MeSH terms
-
Binding, Competitive
-
Clarithromycin / blood*
-
Clarithromycin / pharmacokinetics
-
Clarithromycin / pharmacology*
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme Inhibitors*
-
Cytochrome P-450 Enzyme System / metabolism
-
Enzyme Inhibitors / blood
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Ketoconazole / blood*
-
Ketoconazole / pharmacokinetics
-
Ketoconazole / pharmacology*
-
Liver / drug effects
-
Liver / metabolism*
-
Mixed Function Oxygenases / antagonists & inhibitors*
-
Mixed Function Oxygenases / metabolism
-
Triazolam / blood
-
Triazolam / metabolism
-
Triazolam / pharmacology
Substances
-
Cytochrome P-450 Enzyme Inhibitors
-
Enzyme Inhibitors
-
Triazolam
-
Cytochrome P-450 Enzyme System
-
Mixed Function Oxygenases
-
CYP3A protein, human
-
Cytochrome P-450 CYP3A
-
Clarithromycin
-
Ketoconazole